267 related articles for article (PubMed ID: 27826740)
1. Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.
Swart T; Hurley MJ
CNS Drugs; 2016 Dec; 30(12):1127-1135. PubMed ID: 27826740
[TBL] [Abstract][Full Text] [Related]
2. Lower Affinity of Isradipine for L-Type Ca
Ortner NJ; Bock G; Dougalis A; Kharitonova M; Duda J; Hess S; Tuluc P; Pomberger T; Stefanova N; Pitterl F; Ciossek T; Oberacher H; Draheim HJ; Kloppenburg P; Liss B; Striessnig J
J Neurosci; 2017 Jul; 37(28):6761-6777. PubMed ID: 28592699
[TBL] [Abstract][Full Text] [Related]
3. The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease.
Liss B; Striessnig J
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():263-289. PubMed ID: 30625283
[TBL] [Abstract][Full Text] [Related]
4. Calcium, ageing, and neuronal vulnerability in Parkinson's disease.
Surmeier DJ
Lancet Neurol; 2007 Oct; 6(10):933-8. PubMed ID: 17884683
[TBL] [Abstract][Full Text] [Related]
5. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
Ilijic E; Guzman JN; Surmeier DJ
Neurobiol Dis; 2011 Aug; 43(2):364-71. PubMed ID: 21515375
[TBL] [Abstract][Full Text] [Related]
6. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Wang QM; Xu YY; Liu S; Ma ZG
Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
[TBL] [Abstract][Full Text] [Related]
7. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.
Parkinson Study Group STEADY-PD III Investigators
Ann Intern Med; 2020 May; 172(9):591-598. PubMed ID: 32227247
[TBL] [Abstract][Full Text] [Related]
8. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease.
Chan CS; Gertler TS; Surmeier DJ
Mov Disord; 2010; 25 Suppl 1():S63-70. PubMed ID: 20187241
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.
Simuni T; Borushko E; Avram MJ; Miskevics S; Martel A; Zadikoff C; Videnovic A; Weaver FM; Williams K; Surmeier DJ
Mov Disord; 2010 Dec; 25(16):2863-6. PubMed ID: 20818667
[TBL] [Abstract][Full Text] [Related]
10. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
Parkinson Study Group
Mov Disord; 2013 Nov; 28(13):1823-31. PubMed ID: 24123224
[TBL] [Abstract][Full Text] [Related]
11. Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
Surmeier DJ; Nguyen JT; Lancki N; Venuto CS; Oakes D; Simuni T; Wyse RK
Mov Disord; 2022 Feb; 37(2):334-342. PubMed ID: 34766657
[TBL] [Abstract][Full Text] [Related]
12. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials.
Rees K; Stowe R; Patel S; Ives N; Breen K; Ben-Shlomo Y; Clarke CE
Cochrane Database Syst Rev; 2011 Nov; (11):CD008535. PubMed ID: 22071852
[TBL] [Abstract][Full Text] [Related]
13. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.
Campbell CA; Mackay KB; Patel S; King PD; Stretton JL; Hadingham SJ; Hamilton TC
Exp Neurol; 1997 Nov; 148(1):45-50. PubMed ID: 9398449
[TBL] [Abstract][Full Text] [Related]
14. Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
Venuto CS; Yang L; Javidnia M; Oakes D; James Surmeier D; Simuni T
Ann Clin Transl Neurol; 2021 Mar; 8(3):603-612. PubMed ID: 33460320
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Cronin A; Grealy M
Neuroscience; 2017 Dec; 367():34-46. PubMed ID: 29079063
[TBL] [Abstract][Full Text] [Related]
16. Disease-Modifying Drugs in Parkinson's Disease.
Park A; Stacy M
Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trial Highlights: Phase III Study in Spotlight.
McFarthing K; Simuni T
J Parkinsons Dis; 2019; 9(1):3-4. PubMed ID: 30741695
[No Abstract] [Full Text] [Related]
18. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
Youdim MB; Geldenhuys WJ; Van der Schyf CJ
Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537
[TBL] [Abstract][Full Text] [Related]
20. Isradipine Versus Placebo in Early Parkinson Disease.
Ann Intern Med; 2020 May; 172(9):. PubMed ID: 32227244
[No Abstract] [Full Text] [Related]
[Next] [New Search]
